Akoya Biosciences (NASDAQ:AKYA – Get Rating) will post its quarterly earnings results after the market closes on Monday, August 8th. Analysts expect Akoya Biosciences to post earnings of ($0.34) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
Akoya Biosciences (NASDAQ:AKYA – Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Akoya Biosciences had a negative return on equity of 39.95% and a negative net margin of 86.00%. The company had revenue of $16.89 million for the quarter, compared to analyst estimates of $14.79 million. During the same period last year, the business earned ($2.85) EPS. On average, analysts expect Akoya Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Akoya Biosciences Price Performance
Shares of AKYA opened at $14.08 on Monday. Akoya Biosciences has a 12-month low of $8.02 and a 12-month high of $21.21. The business’s fifty day moving average is $11.95 and its 200 day moving average is $11.26. The company has a quick ratio of 3.63, a current ratio of 3.98 and a debt-to-equity ratio of 0.31. The stock has a market cap of $529.27 million, a P/E ratio of -9.92 and a beta of 0.65.
Analyst Upgrades and Downgrades
Hedge Funds Weigh In On Akoya Biosciences
Large investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in Akoya Biosciences by 1.4% during the 1st quarter. BlackRock Inc. now owns 777,001 shares of the company’s stock valued at $8,538,000 after acquiring an additional 10,737 shares in the last quarter. Vanguard Group Inc. lifted its stake in Akoya Biosciences by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 700,823 shares of the company’s stock valued at $7,702,000 after acquiring an additional 25,845 shares in the last quarter. State Street Corp lifted its stake in Akoya Biosciences by 17.5% during the 1st quarter. State Street Corp now owns 182,291 shares of the company’s stock valued at $2,003,000 after acquiring an additional 27,194 shares in the last quarter. Candriam Luxembourg S.C.A. lifted its stake in Akoya Biosciences by 216.7% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 159,300 shares of the company’s stock valued at $1,751,000 after acquiring an additional 109,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Akoya Biosciences by 12.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 67,401 shares of the company’s stock worth $741,000 after purchasing an additional 7,243 shares during the period. 39.90% of the stock is currently owned by institutional investors.
About Akoya Biosciences
Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
- Get a free copy of the StockNews.com research report on Akoya Biosciences (AKYA)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.